$TCRR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TCR2 THERAPEUTICS INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in TCR2 THERAPEUTICS INC.. Get notifications about new insider transactions in TCR2 THERAPEUTICS INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Grant | A | 16.12 | 708 | 11,416 | 3,751 | 3 K to 3.8 K (+23.27 %) |
| Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Grant | A | 10.10 | 1,118 | 11,290 | 3,043 | 1.9 K to 3 K (+58.08 %) |
| Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Justice Angela | Chief People Office ... | Grant | A | 16.12 | 326 | 5,257 | 326 | 0 to 326 |
| Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Grant | A | 16.12 | 686 | 11,061 | 4,085 | 3.4 K to 4.1 K (+20.18 %) |
| Mar 08 2021 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Grant | A | 10.10 | 1,132 | 11,431 | 3,399 | 2.3 K to 3.4 K (+49.93 %) |
| Feb 04 2021 | TCRR | TCR2 THERAPEUTICS ... | Tomasello Shawn | Director | Option Exercise | A | 26.33 | 4,177 | 109,980 | 4,177 | |
| Feb 04 2021 | TCRR | TCR2 THERAPEUTICS ... | Tomasello Shawn | Director | Option Exercise | A | 26.33 | 15,191 | 399,979 | 15,191 | |
| Dec 23 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | M | 0.74 | 7,000 | 5,180 | 28,732 | |
| Dec 23 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Buy | M | 0.74 | 7,000 | 5,180 | 45,850 | 38.9 K to 45.9 K (+18.02 %) |
| Dec 16 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Option Exercise | M | 5.88 | 2,000 | 11,760 | 102,558 | |
| Dec 16 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Sell | S | 35.00 | 2,000 | 70,000 | 1,473 | 3.5 K to 1.5 K (-57.59 %) |
| Dec 16 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Buy | M | 5.88 | 2,000 | 11,760 | 3,473 | 1.5 K to 3.5 K (+135.78 %) |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Webster Stephen W | Director | Option Exercise | A | 31.83 | 12,100 | 385,143 | 12,100 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Option Exercise | A | 31.83 | 92,000 | 2,928,360 | 92,000 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Option Exercise | A | 31.83 | 101,000 | 3,214,830 | 101,000 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Option Exercise | A | 31.38 | 245,000 | 7,688,100 | 245,000 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Baeuerle Patrick | Director | Option Exercise | A | 31.83 | 12,100 | 385,143 | 12,100 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Justice Angela | Chief People Office ... | Option Exercise | A | 31.83 | 67,000 | 2,132,610 | 67,000 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Option Exercise | A | 31.83 | 12,100 | 385,143 | 12,100 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Hoos Axel | Director | Option Exercise | A | 31.83 | 12,100 | 385,143 | 12,100 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | A | 31.83 | 76,000 | 2,419,080 | 76,000 | |
| Dec 11 2020 | TCRR | TCR2 THERAPEUTICS ... | Allen Andrew R | Director | Option Exercise | A | 31.83 | 12,100 | 385,143 | 12,100 | |
| Nov 19 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Option Exercise | M | 5.88 | 2,000 | 11,760 | 104,558 | |
| Nov 19 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Sell | S | 30.00 | 1,666 | 49,980 | 1,473 | 3.1 K to 1.5 K (-53.07 %) |
| Nov 19 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Sell | S | 30.00 | 2,000 | 60,000 | 3,139 | 5.1 K to 3.1 K (-38.92 %) |
| Nov 19 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Buy | M | 5.88 | 2,000 | 11,760 | 5,139 | 3.1 K to 5.1 K (+63.71 %) |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | M | 0.74 | 10,002 | 7,401 | 25,730 | |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | M | 0.74 | 9,998 | 7,399 | 12,348 | |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Sell | S | 25.10 | 10,002 | 251,050 | 38,850 | 48.9 K to 38.9 K (-20.47 %) |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Buy | M | 0.74 | 10,002 | 7,401 | 48,852 | 38.9 K to 48.9 K (+25.75 %) |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Sell | S | 25.10 | 9,998 | 250,950 | 38,850 | 48.8 K to 38.9 K (-20.47 %) |
| Nov 13 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Buy | M | 0.74 | 9,998 | 7,399 | 48,848 | 38.9 K to 48.8 K (+25.73 %) |
| Nov 02 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Science Offic ... | Option Exercise | M | 0.74 | 20,000 | 14,800 | 22,346 | |
| Nov 02 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Science Offic ... | Sell | S | 19.10 | 20,000 | 382,000 | 38,850 | 58.9 K to 38.9 K (-33.98 %) |
| Nov 02 2020 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Science Offic ... | Buy | M | 0.74 | 20,000 | 14,800 | 58,850 | 38.9 K to 58.9 K (+51.48 %) |
| May 04 2020 | TCRR | TCR2 THERAPEUTICS ... | Webster Stephen W | Director | Option Exercise | A | 9.54 | 10,482 | 99,998 | 10,482 | |
| Apr 15 2020 | TCRR | TCR2 THERAPEUTICS ... | Hoos Axel | Director | Option Exercise | A | 10.42 | 9,596 | 99,990 | 9,596 | |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 7.94 | 648 | 5,145 | 0 | 648 to 0 (-100.00 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 7.41 | 3,140 | 23,267 | 648 | 3.8 K to 648 (-82.89 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 6.83 | 3,120 | 21,310 | 3,788 | 6.9 K to 3.8 K (-45.17 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 6.49 | 3,009 | 19,528 | 6,908 | 9.9 K to 6.9 K (-30.34 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 6.60 | 17,723 | 117,043 | 9,917 | 27.6 K to 9.9 K (-64.12 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | S | 6.52 | 52,000 | 338,894 | 27,640 | 79.6 K to 27.6 K (-65.29 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | J | 0.00 | 217,974 | 0 | 79,640 | 297.6 K to 79.6 K (-73.24 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | J | 0.00 | 196,177 | 0 | 297,614 | 493.8 K to 297.6 K (-39.73 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Sell | J | 0.00 | 212,560 | 0 | 493,791 | 706.4 K to 493.8 K (-30.09 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President & CEO | Grant | A | 10.10 | 1,287 | 12,999 | 2,267 | 980 to 2.3 K (+131.33 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President & CEO | Grant | A | 12.75 | 980 | 12,495 | 980 | 0 to 980 |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Grant | A | 10.10 | 1,082 | 10,928 | 1,925 | 843 to 1.9 K (+128.35 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Grant | A | 12.75 | 843 | 10,748 | 843 | 0 to 843 |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Grant | A | 10.10 | 1,473 | 14,877 | 3,139 | 1.7 K to 3.1 K (+88.42 %) |
| Mar 27 2020 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Grant | A | 12.75 | 1,666 | 21,242 | 1,666 | 0 to 1.7 K |
| Dec 26 2019 | TCRR | TCR2 THERAPEUTICS ... | Baeuerle Patrick | Director | Sell | S | 15.44 | 84,907 | 1,310,964 | 350,786 | 435.7 K to 350.8 K (-19.49 %) |
| Dec 26 2019 | TCRR | TCR2 THERAPEUTICS ... | Baeuerle Patrick | Director | Sell | S | 15.16 | 32,022 | 485,454 | 435,693 | 467.7 K to 435.7 K (-6.85 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Option Exercise | A | 16.10 | 5,000 | 80,500 | 5,000 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Option Exercise | A | 16.10 | 72,100 | 1,160,810 | 72,100 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President and CEO | Option Exercise | A | 16.10 | 168,000 | 2,704,800 | 168,000 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Allen Andrew R | Director | Option Exercise | A | 16.10 | 5,000 | 80,500 | 5,000 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Option Exercise | A | 16.10 | 50,000 | 805,000 | 50,000 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | A | 16.10 | 50,000 | 805,000 | 50,000 | |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | J | 0.00 | 13,847 | 0 | 161,024 | 174.9 K to 161 K (-7.92 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | J | 0.00 | 586,153 | 0 | 713,723 | 1.3 M to 713.7 K (-45.09 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 16.47 | 35,323 | 581,819 | 155,986 | 191.3 K to 156 K (-18.46 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 16.47 | 6,642 | 109,403 | 82,575 | 89.2 K to 82.6 K (-7.44 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 2,433 | 41,376 | 191,309 | 193.7 K to 191.3 K (-1.26 %) |
| Dec 20 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 458 | 7,789 | 89,217 | 89.7 K to 89.2 K (-0.51 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 4,153 | 73,311 | 1,299,876 | 1.3 M to 1.3 M (-0.32 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 1,054 | 18,606 | 330,238 | 331.3 K to 330.2 K (-0.32 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 1,381 | 24,378 | 432,319 | 433.7 K to 432.3 K (-0.32 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 1,155 | 20,389 | 361,665 | 362.8 K to 361.7 K (-0.32 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.62 | 30,475 | 537,067 | 1,304,029 | 1.3 M to 1.3 M (-2.28 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.62 | 7,741 | 136,421 | 331,292 | 339 K to 331.3 K (-2.28 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.62 | 10,135 | 178,611 | 433,700 | 443.8 K to 433.7 K (-2.28 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.62 | 8,479 | 149,427 | 362,820 | 371.3 K to 362.8 K (-2.28 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 75,067 | 1,325,015 | 1,334,504 | 1.4 M to 1.3 M (-5.33 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 19,070 | 336,606 | 339,033 | 358.1 K to 339 K (-5.33 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 24,966 | 440,677 | 443,835 | 468.8 K to 443.8 K (-5.33 %) |
| Dec 11 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.65 | 20,886 | 368,661 | 371,299 | 392.2 K to 371.3 K (-5.33 %) |
| Oct 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 15.16 | 2,085 | 31,603 | 1,409,571 | 1.4 M to 1.4 M (-0.15 %) |
| Oct 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 15.16 | 530 | 8,033 | 358,103 | 358.6 K to 358.1 K (-0.15 %) |
| Oct 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 15.16 | 693 | 10,504 | 392,185 | 392.9 K to 392.2 K (-0.18 %) |
| Oct 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 15.16 | 580 | 8,791 | 392,185 | 392.8 K to 392.2 K (-0.15 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 5,516 | 95,490 | 1,411,656 | 1.4 M to 1.4 M (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,401 | 24,253 | 358,633 | 360 K to 358.6 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,835 | 31,766 | 469,464 | 471.3 K to 469.5 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 5,516 | 95,490 | 1,411,656 | 1.4 M to 1.4 M (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 351 | 6,076 | 89,675 | 90 K to 89.7 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,401 | 24,253 | 358,633 | 360 K to 358.6 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 683 | 11,824 | 174,871 | 175.6 K to 174.9 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,835 | 31,766 | 469,464 | 471.3 K to 469.5 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,535 | 26,573 | 392,765 | 394.3 K to 392.8 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 351 | 6,076 | 89,675 | 90 K to 89.7 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 197,343 | 3,539,426 | 1,417,172 | 1.6 M to 1.4 M (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 683 | 11,824 | 174,871 | 175.6 K to 174.9 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 50,134 | 899,173 | 360,034 | 410.2 K to 360 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.31 | 1,535 | 26,573 | 392,765 | 394.3 K to 392.8 K (-0.39 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 65,633 | 1,177,154 | 471,299 | 536.9 K to 471.3 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 197,343 | 3,539,426 | 1,417,172 | 1.6 M to 1.4 M (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 12,537 | 224,856 | 90,026 | 102.6 K to 90 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 50,134 | 899,173 | 360,034 | 410.2 K to 360 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 24,446 | 438,449 | 175,554 | 200 K to 175.6 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 65,633 | 1,177,154 | 471,299 | 536.9 K to 471.3 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 54,907 | 984,779 | 394,300 | 449.2 K to 394.3 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 12,537 | 224,856 | 90,026 | 102.6 K to 90 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 24,446 | 438,449 | 175,554 | 200 K to 175.6 K (-12.22 %) |
| Sep 24 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.94 | 54,907 | 984,779 | 394,300 | 449.2 K to 394.3 K (-12.22 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.55 | 12,214 | 214,414 | 102,563 | 114.8 K to 102.6 K (-10.64 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 10,559 | 179,653 | 114,777 | 125.3 K to 114.8 K (-8.42 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 3,700 | 62,925 | 125,336 | 129 K to 125.3 K (-2.87 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 6,700 | 113,941 | 129,036 | 135.7 K to 129 K (-4.94 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 1,200 | 20,414 | 135,736 | 136.9 K to 135.7 K (-0.88 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 29,128 | 495,479 | 136,936 | 166.1 K to 136.9 K (-17.54 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.00 | 3 | 51 | 166,064 | 166.1 K to 166.1 K (0.00 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.03 | 100 | 1,703 | 166,067 | 166.2 K to 166.1 K (-0.06 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.00 | 500 | 8,500 | 166,167 | 166.7 K to 166.2 K (-0.30 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.55 | 12,214 | 214,414 | 102,563 | 114.8 K to 102.6 K (-10.64 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 10,559 | 179,653 | 114,777 | 125.3 K to 114.8 K (-8.42 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 3,700 | 62,925 | 125,336 | 129 K to 125.3 K (-2.87 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 6,700 | 113,941 | 129,036 | 135.7 K to 129 K (-4.94 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 1,200 | 20,414 | 135,736 | 136.9 K to 135.7 K (-0.88 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.01 | 29,128 | 495,479 | 136,936 | 166.1 K to 136.9 K (-17.54 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.00 | 3 | 51 | 166,064 | 166.1 K to 166.1 K (0.00 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.03 | 100 | 1,703 | 166,067 | 166.2 K to 166.1 K (-0.06 %) |
| Sep 05 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | 10% Owner | Sell | S | 17.00 | 500 | 8,500 | 166,167 | 166.7 K to 166.2 K (-0.30 %) |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Baeuerle Patrick | Director | Option Exercise | A | 16.11 | 59,850 | 964,184 | 59,850 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Option Exercise | A | 16.11 | 6,270 | 101,010 | 6,270 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Cardama Alfonso Quintas | Chief Medical Offic ... | Option Exercise | A | 16.11 | 211,302 | 3,404,075 | 211,302 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Allen Andrew R | Director | Option Exercise | A | 16.11 | 6,270 | 101,010 | 6,270 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Menzel Garry E | President & CEO | Option Exercise | A | 16.11 | 486,106 | 7,831,168 | 486,106 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Somaiya Mayur Ian | Chief Financial Off ... | Option Exercise | A | 16.11 | 152,307 | 2,453,666 | 152,307 | |
| Apr 12 2019 | TCRR | TCR2 THERAPEUTICS ... | Hofmeister Robert | Chief Scientific Of ... | Option Exercise | A | 16.11 | 127,512 | 2,054,218 | 127,512 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 666,667 | 10,000,005 | 3,370,982 | 2.7 M to 3.4 M (+24.65 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Option Exercise | C | 0.00 | 17,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | P | 15.00 | 706,666 | 10,599,990 | 4,050,865 | 3.3 M to 4.1 M (+21.13 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | C | 0.00 | 322,901 | 0 | 3,344,199 | 3 M to 3.3 M (+10.69 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | C | 0.00 | 2,825,396 | 0 | 3,021,298 | 195.9 K to 3 M (+1,442.25 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Option Exercise | C | 0.00 | 17,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | P | 15.00 | 706,666 | 10,599,990 | 4,050,865 | 3.3 M to 4.1 M (+21.13 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | C | 0.00 | 322,901 | 0 | 3,344,199 | 3 M to 3.3 M (+10.69 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | C | 0.00 | 2,825,396 | 0 | 3,021,298 | 195.9 K to 3 M (+1,442.25 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 2,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 2,540,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 1,200,000 | 0 | 0 |